AI assistant
UCB — AGM Information 2026
May 13, 2026
4017_rns_2026-05-13_73a18e18-853f-4def-bf07-9c2a17ae3cbe.pdf
AGM Information
Open in viewerOpens in your device viewer
UCB
Inspired by patients.
Driven by science.
UCB SA/NV
Public limited liability company
Allée de la Recherche 60, 1070 Brussels
Enterprise nr. 0403.053.608 (RLE Brussels)
www.ucb.com
UCB SA/NV (hereafter the "Company")
MINUTES OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS
HELD AT THE REGISTERED OFFICE
ON THURSDAY 30 APRIL 2026 AT 11:00 AM
FREE TRANSLATION FOR INFORMATION PURPOSES ONLY
MINUTES
OPENING OF THE MEETING
The general meeting of the shareholders (hereinafter the "General Meeting") is opened at 11.00 a.m., at the Company's registered office, located Allée de la Recherche 60, 1070 Brussels and is chaired by the Chairman of the Board of Directors, Mr. Jonathan Peacock in accordance with the Company's Articles of Associations.
Before setting up the Bureau of the General Meeting, the Chair welcomes the shareholders at the registered office.
The Chair then invites Mr. Xavier Michel, Secretary General of UCB SA/NV, to provide the shareholders with some technical explanations regarding the voting and the translation devices. Simultaneous translation in French, Dutch and English is available to the shareholders and proxy holders present at the meeting.
A. Bureau
Composition
The Chair invites the following people to constitute the bureau of the assembly, also in accordance with the Company's articles of association:
- he calls Mr. Xavier Michel, Secretary General of UCB to the function of Secretary of the General Meeting;
- he calls Ms. Davina Devleeschouwer and Ms. Luminita Grigorescu, UCB employees, as scrutineers;
- he finally calls the following other directors of the Company present at the meeting to be part of the Bureau: Mr. Charles-Antoine Janssen, Vice-Chair of the Board, Mr. Jean-Christophe Tellier, CEO and Chairman of the Executive Committee of the Company, Mrs. Jan Berger, Mrs. Kay Davies, Mr. Stef Heylen, Mr. Pierre Gurdjian, Mr. Cyril Janssen, Mr. Cédric van Rijckevorsel, Mr. Ulf Wiinberg, Mrs. Nefertiti Greene, Mrs. Fiona Powrie, and Mr. Rodolfo Savitzky.
The statutory auditor, Mazars, represented by Mr. Sébastien Schueremans is also present.
A few employees of UCB, as well as some members of the Executive Committee, are attending the meeting and, if necessary, will be asked to assist the Board in the context of the questions and answer session.
The proxyholder of the shareholders, designated by the Board of Directors, Mr. Bart De Vry, is present.
Review by the bureau
The Chair invites the Vice-Chair to report about the verifications and reviews made by the bureau in view of the constitution of the General Meeting, both during and upon closing of the attendance registration formalities.
(i) Convening notices:
The convening notice, containing the agenda and all other documents required by law, have been published in a timely manner in accordance with the articles of association and articles 7:128 and following of the Belgian Code of Companies & Associations ("BCCA").
The Chair reminds and the bureau acknowledges that the text of the agenda, the convening notice as well as all other documents prescribed by law (pursuant to articles 7:128 and following of the BCCA) were duly published and available as from 27 March 2026 on the UCB website. In addition, a communication was sent through a press agency (Notified/GlobeNewswire) on the same date to ensure the international distribution of the convening notice and of the other documents prescribed by the Belgian Code of Companies and Associations.
The convening notice was also sent electronically to holders of dematerialized shares and their financial intermediaries via the Lumi Connect and Proxymity Platforms.
Finally, the bureau notes that a convening notice was sent on 27 March 2026 to the registered shareholders, either by email (for shareholders who had previously accepted this method of communication), or by ordinary mail (for the others).
Additionally, all documents relating to this General Meeting have been made available for consultation by the shareholders during business days and office hours at the Company's registered office as from 27 March 2026. Shareholders were also able to obtain a copy of these documents free of charge, upon request.
The convening letter was also sent by email to the members of the Board of Directors and the statutory auditor in accordance with the modalities previously agreed with them and in accordance with the BCCA.
The Chair invites the scrutineers to initial the documents relating to the completion of the formalities mentioned above.
The meeting was reminded that the economic and financial information was provided to the Works Councils in view of their respective meetings held on 22 April 2026 in accordance with the provisions of article 16 of the Royal Decree of 27 November 1973. The sustainability information was also provided to the Works Councils in accordance with article 3:32/4 BCCA for discussion at their respective meetings held on 19 and 24 March 2026.
No objections were raised by either Works Council against the information provided to them.
(ii) Verification of the powers of the attendees:
After verification it is confirmed that the shareholders included in the attendance list have fulfilled the legal and statutory attendance formalities in due time. It is reminded that in the framework of the General Meeting, the shareholders had the choice to participate to this meeting, in person or by proxy. The shareholders who chose to appoint a proxyholder, had the choice to be represented by the proxyholder of their choice or by Mr. Bart De Vry, the proxyholder designated by the Board of Directors. The attendance list therefore includes the shareholders who have fulfilled the attendance formalities (in person or by proxy), including via the Lumi Connect platform, provided that the Company has received evidence that these shareholders were holders, of the shares for which they
intended to participate in the voting at this meeting on the registration date. The attendance list was presented to the bureau for verification and will be retained.
(iii) Attendance list:
It results from the attendance list, that the shareholders, who have fulfilled the legal and statutory formalities in due time, represent 161 825 557 capital shares, with one vote each (i.e. an attendance of 83.20 % out of a total of 194 505 658 issued shares, or an attendance of 84.89 % out of a total of 190 635 094 shares entitled to vote, taking into consideration 3 870 564 own shares held by UCB of which the voting rights are suspended). In accordance with article 39 of the articles of association, this meeting can validly deliberate, irrespective of the number of shares represented and decide by majority voting.
This Chair acknowledges that the General Meeting is duly constituted and may validly deliberate and vote on the agenda items.
B. Agenda
Given that the agenda was communicated before the meeting to all shareholders (at least 30 days before the meeting), the assembly exempts the chair from reading out the agenda during the meeting. The agenda of the annual general meeting is indicated below:
ORDINARY PART
- Report of the Board of Directors on the annual accounts for the financial year ended 31 December 2025
- Report of the statutory auditor on the annual accounts for the financial year ended 31 December 2025
- Communication of the consolidated annual accounts of the UCB Group relating to the financial year ended 31 December 2025 and the consolidated report of the Board of Directors on these accounts. Such documents are included in the Integrated Annual Report 2025. The consolidated report of the Board of Directors also comprises the corporate governance statement and the sustainability information to be prepared pursuant to the Belgian Code of Companies and Associations (BCCA)
- Approval of the annual accounts of UCB SA/NV for the financial year ended 31 December 2025 and appropriation of the results
Proposed resolution:
The General Meeting approves the annual accounts of UCB SA/NV for the financial year ended 31 December 2025 and the appropriation of the results reflected therein, including the approval of a gross dividend of € 1.45 per share(*).
(*) The UCB shares held by UCB SA/NV (own shares) are not entitled to a dividend. Therefore, the aggregate amount to be distributed to the shareholders may fluctuate depending on the number of UCB shares held by UCB SA/NV (own shares) on the dividend approval date.
- Approval of the remuneration report for the financial year ended 31 December 2025
The BCCA requires the General Meeting to approve the remuneration report each year by separate vote. This report includes a description of the application of the remuneration policy and information on the remuneration of the members of the Board of Directors and of the Executive Committee, for the financial year ended 31 December 2025.
Proposed resolution:
The General Meeting approves the remuneration report for the financial year ended 31 December 2025.
- Discharge in favour of the directors
Pursuant to the BCCA, the General Meeting must, after approval of the annual accounts, vote on the discharge of liability of the directors for the financial year ended on 31 December 2025.
Proposed resolution:
The General Meeting grants discharge to the directors for the performance of their duties during the financial year ended 31 December 2025.
- Discharge in favour of the statutory auditor
Pursuant to the BCCA, the General Meeting must, after approval of the annual accounts, vote on the discharge of liability of the statutory auditor (Forvis Mazars) in relation to the performance of its duties during the financial year ended 31 December 2025.
Proposed resolution:
The General Meeting grants discharge to the statutory auditor for the performance of its duties during the financial year ended 31 December 2025.
- Directors: renewal of mandates of directors
The mandates of Mr. Jean-Christophe Tellier, executive director and the mandate of Mr Cédric van Rijckevorsel, director will expire at this General Meeting.
The Board of Directors, following the recommendation of the GNCC, proposes renewing the mandate of Mr. Jean-Christophe Tellier and Mr. Cédric van Rijckevorsel for 4 years (until the end of the ordinary General Meeting of 2030). Mr. Jean-Christophe Tellier being the CEO of UCB is not eligible to qualify as independent director. He is also the only executive director on the Board of UCB. Mr. Cédric van Rijckevorsel is a representative of UCB's reference shareholder and, as such, is not eligible to qualify as independent director.
The mandate of Mrs. Kay Davies, independent director, will expire at this General Meeting as well and will not be renewed. The Board of directors would like to thank Mrs. Davies for her outstanding contribution over the last twelve years, to the Board as whole and as Chair of the GNCC and member of the Scientific Committee.
The Board of directors also confirms that, subject to the above-mentioned renewals by the General Meeting, the Board of Directors, as well as each of its special committees, will continue to be composed of a majority of independent directors. The Board composition will also continue to be compliant with the requirement of the BCCA that at least one third of the members of the Board must be of a different sex than that of the other members.
The curriculum vitae, information on other board mandates and skills of these directors are available on the website of UCB (https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeting-2026).
Proposed resolutions:
8.1 The General Meeting renews the appointment of Mr. Jean-Christophe Tellier as director for a term of four years until the close of the ordinary General Meeting of 2030.
8.2 The General Meeting renews the appointment of Mr. Cédric van Rijckevorsel as director for a term of four years until the close of the ordinary General Meeting of 2030.
SPECIAL PART
- Renewal of approval of a change of control provisions in the EMTN Program - art. 7:151 of the BCCA
Pursuant to article 7:151 of the BCCA, the General Meeting is solely competent to approve so-called ‘change of control’ clauses, i.e., provisions whereby third parties are granted rights having a substantial influence on the assets of the Company or causing a substantial debt or liability for the Company, if the exercise of such rights depends on the launch of a public takeover bid on the shares of the Company or a change of control thereof. These clauses are standard requests from our creditors and/or in the legal documentation of our financing arrangements.
UCB SA/NV has established a Euro Medium Term Note Program on 6 March 2013 for an amount of EUR 5 000 000 000, with last update of the Base Prospectus on 17 October 2023, as this program may be further amended, extended or updated from time to time (the “EMTN Program”). The terms of the EMTN Program provide for a change of control clause - condition 5 (e) (i) - under which, for any of the Notes issued under the EMTN Program where a change of control put is included in the relevant final terms, any and all of the holders of such notes can, in certain circumstances, require UCB SA/NV to redeem that Note, following a change of control at the level of UCB SA/NV, upon exercise of the change of control put, for a value equal to the put redemption amount increased with, if appropriate, interest accrued until the date of exercise of the change of control put (all as more particularly described in the Base Prospectus of the EMTN Program).
In accordance with article 7:151 of the BCCA, this clause must be approved by the General Meeting, and it is hereby proposed to renew this approval for any series of notes issued under the EMTN Program including such clause during the next 12 months.
Proposed resolution:
Pursuant to article 7:151 of the BCCA, the General Meeting renews its approval: (i) of condition 5 (e) (i) of the Terms and Conditions of the EMTN Program (Redemption at the Option of Noteholders – Upon a Change of Control (Change of Control Put)), in respect of any series of notes to which such condition is made applicable being issued under the Program, to the extent the Program is renewed to allow for such issuance, from 30 April 2026 until 29 April 2027, under which any and all of the holders of the relevant notes can, in certain circumstances when a Change of Control at the level of UCB SA/NV occurs, require UCB SA/NV to redeem that note on the Change of Control Put Date at the Put Redemption Amount together, if applicable, with interest accrued to such Change of Control Put Date, following a Change of Control of UCB SA/NV; and (ii) of any
other provision of the EMTN Program or notes issued under the EMTN Program granting rights to third parties which could affect an obligation on UCB SA/NV where in each case the exercise of these rights is dependent on the occurrence of a Change of Control.
Message from the CEO
The Chairman then gives the floor to Mr. Jean-Christophe Tellier, CEO and Chairman of the Executive Committee, for his speech which covers the presentation to the General Meeting of the group's activities and results for the 2025 financial year.
Mr. Jean-Christophe Tellier speech starts by a short video regarding epilepsy care in Rwanda, for the purpose of illustrating UCB’s sense of purpose and patient value creation.
Communication of the reports of the Board of Directors and the statutory auditor
Moving on to the 3 first items of the agenda of the meeting (non-voting items), the Chair referred to the following communications:
(i) the report of the Board of Directors on the annual accounts for the financial year ended 31 December 2025;
(ii) the report of the statutory auditor on the annual accounts for the financial year ended 31 December 2025; and
(iii) the consolidated annual accounts of the UCB group relating to the financial year ended 31 December 2025.
Referring to the consolidated accounts, the Chair referred to the presentation of Jean-Christophe Tellier. In 2025, the UCB Group revenues reached EUR 7 741 million, resulting in underlying profitability adjusted EBITDA of EUR 2 636 million and core earnings per share of EUR 9.99.
With the agreement of the statutory auditor, the assembly also exempts the bureau from reading the reports of the Board of Directors and the statutory auditor relating to the 2025 annual accounts, considering that Mr. Jean-Christophe Tellier and the Chair already reported on the financial results to the shareholders and considering, moreover, that these reports were made available to shareholders before this General Meeting.
Comments on the 2025 remuneration report
The 2025 Remuneration Report was commented on by the Chair of the GNCC, Dame Kay Davies, before being submitted for approval to the General Meeting.
7
Q&A Session
Before addressing the voting items of the agenda, the Chair recalls that, in accordance with article 7:139 BCCA, under certain conditions, shareholders are entitled to submit questions (i) in writing prior to the General Meeting or (ii) orally during the General Meeting, to the Board of Directors or the statutory auditor regarding their reports or items on the agenda. The questions are answered during the General Meeting provided (i) the shareholders concerned have complied with all required admission formalities and (ii) any communication of information or fact in response to such question does not prejudice the Company's business interests or the confidentiality undertakings of UCB SA/NV, its directors and statutory auditor.
The Chair confirms that the shareholders had the opportunity to address their questions in writing to the Company previously, in accordance with the Belgian Code of Companies and Associations. Questions had to be received by UCB by April 24, 2026 at 3:00 p.m. CEST at the latest.
The Chair indicates that two questions were asked in writing. The first question relates to UCB's pipeline evolution and potential future add-on cures and application and the second one to the products to be manufactured in UCB's new US facility and the view of UCB on the associated growth and investments. These questions, as well as the answers from the Company, are read during the meeting by the Secretary General.
The Chair then moves on to the "live" Q&A session, after insisting on the fact that shareholders who are present or represented today are only allowed to ask their questions during this Q&A session, and that this includes questions relating to the extraordinary meeting which will follow.
The Chair notes that there are questions from the assembly and invites each shareholder to speak up for the purpose of the live Q&A session. Three shareholders asked questions, on the below mentioned topics:
- cohort composition in medical studies and potential biases;
- the environmental impact of UCB on air and water and whether UCB is financing any studies in this regard;
- the potential for UCB to influence scope 3 emissions, which are primarily attributed to suppliers;
- the proposed dividend amount and the number of shares repurchased by the company;
- the acquisition of Neurona Therapeutics;
- whether UCB has any intention to achieve B Corp certification;
- the fictional futuristic scenarios presented by UCB to its management during a retreat and the lessons learned from such experience;
- the proposed appointment of Jean-Christophe Tellier as director of Solvac and whether this is compliant with the governance of UCB;
- UCB's shareholding transparency thresholds; and
- UCB's perspective regarding the competitive environment for BIMZELX®.
After all such questions were answered, the Chairman noted that all the questions raised by shareholders have been answered satisfactorily, in full and in detail.
8
C. Voting
The Chair thereafter opens the voting session on the resolutions set out in the agenda proposed to the General Meeting.
As a reminder, shareholders had the opportunity to vote by proxy prior to the General Meeting. All the votes cast by proxy and validly received by the Company before April 24, 2026 at 3:00 pm CEST at the latest, have been taken into account and are reflected below in the results of the votes for each of the proposed decisions on items 4 to 9 of the agenda.
Mr. Xavier Michel takes over and provides technical explanation on the use of the voting device and makes a test of the voting system with the assembly.
The voting test having been conclusive, before opening the votes, the Chair addresses the agenda and reminds the General Meeting that items 1 to 3 are non-voting items. As mentioned above, the bureau has been exempted from reading the reports referred under those items:
- Report of the Board of Directors on the annual accounts for the financial year ended 31 December 2025
- Report of the statutory auditor on the annual accounts for the financial year ended 31 December 2025
- Communication of the consolidated annual accounts of the UCB Group relating to the financial year ended 31 December 2025 and the consolidated report of the Board of Directors on these accounts. Such documents are included in the Integrated Annual Report 2025. The consolidated report of the Board of Directors also comprises the corporate governance statement and the sustainability information to be prepared pursuant to the Belgian Code of Companies and Associations (BCCA)
The Chair then proceeds with the items on the agenda requiring a vote by the meeting. Before going to the votes, the Secretary carries out a final formal check of the composition of the General Meeting. It appears from the latest version of the attendance list that it remains unchanged in comparison with the first verification and that then, out of the aforementioned total of 190 635 094 share with voting right, 161 825 557 shares are validly present or represented, each giving right to one vote, i.e. an attendance of 84.89% (an attendance quorum for the Annual General Meeting, ordinary and special parts, is not required). The calculation of the required majorities will therefore be made based on the number of shares duly present or represented.
9
4. Approval of the annual accounts of UCB SA/NV for the financial year ended 31 December 2025 and appropriation of the results
The Chair submits to the General Meeting the annual accounts of UCB SA/NV for the financial year ended 31 December 2025 and the proposed appropriation of the results.
Taking into account the number of 3 870 564 own shares held by UCB on the date of this assembly and which are not entitled to the dividend, the following appropriation is proposed:
- Profit to be distributed EUR 400 005 798
- Transfer to available reserves EUR 100 000 000
- Transfer to results carried carried forward EUR 23 981 823
- Allocation to shareholders of a gross dividend of EUR 276 420 886
The above appropriation proposal allows for the distribution of a gross dividend of EUR 1.45 per share, giving right, against presentation of coupon n° 29, to a net dividend per share of EUR 1.015 (in the event that the applicable Belgian withholding tax is 30%; lower withholding tax rates being applicable as the case may be, depending on the situation of the shareholder). The dividend shall be payable to the shareholders on 6 May 2026.
The Chair then calls for a vote on the approval of the financial statements for 2025 and the proposed appropriation of the results, including the gross dividend distribution of EUR 1.45 per share proposed above.
The General Meeting approves the annual accounts as of 31 December 2025 and the proposed appropriation of the results, including the proposed dividend distribution per share, as follows:
| For | 161 451 888 | 99.91% |
|---|---|---|
| Against | 151 055 | 0.09% |
| Abstention | 219 160 |
5. Approval of the remuneration report for the financial year ended 31 December 2025
The General Meeting approves the remuneration report of UCB SA/NV as follows:
| For | 151 908 481 | 95.01% |
|---|---|---|
| Against | 7 977 455 | 4.99% |
| Abstention | 1 936 168 |
10
- Discharge in favour of the directors
The General Meeting grants discharge to the directors for the performance of their mandates during the financial year ended 31 December 2025 as follows:
| For | 156 488 992 | 97.02% |
|---|---|---|
| Against | 4 810 575 | 2.98% |
| Abstention | 522 537 |
- Discharge in favour of the statutory auditor
The General Meeting grants discharge to the statutory auditor for the performance of his duties during the financial year ended 31 December 2025 as follows:
| For | 157 511 925 | 97.65% |
|---|---|---|
| Against | 3 787 792 | 2.35% |
| Abstention | 521 936 |
- Directors: renewal of mandates of directors
The mandates of Mr. Jean-Christophe Tellier, executive director and the mandate of Mr Cédric van Rijckevorsel, director will expire at this General Meeting.
The Board of Directors, following the recommendation of the GNCC, proposes renewing the mandate of Mr. Jean-Christophe Tellier and Mr. Cédric van Rijckevorsel for 4 years (until the end of the ordinary General Meeting of 2030). Mr. Jean-Christophe Tellier being the CEO of UCB is not eligible to qualify as independent director. He is also the only executive director on the Board of UCB. Mr. Cédric van Rijckevorsel is a representative of UCB's reference shareholder and, as such, is not eligible to qualify as independent director.
The mandate of Mrs. Kay Davies, independent director, will expire at this General Meeting as well and will not be renewed. The Board of directors would like to thank Mrs. Davies for her outstanding contribution over the last twelve years, to the Board as whole and as Chair of the GNCC and member of the Scientific Committee.
The Board of directors also confirms that, subject to the above-mentioned renewals by the General Meeting, the Board of Directors, as well as each of its special committees, will continue to be composed of a majority of independent directors. The Board composition will also continue to be compliant with the requirement of the BCCA that at least one third of the members of the Board must be of a different sex than that of the other members.
8.1 The General Meeting renews the appointment of Mr. Jean-Christophe Tellier as director for a term of four years until the close of the ordinary General Meeting of 2030.
This resolution is approved as follows:
| For | 154 762 221 | 95.75% |
|---|---|---|
| Against | 6 866 577 | 4.25% |
| Abstention | 193 166 |
8.2 The General Meeting renews the appointment of Mr. Cédric van Rijckevorsel as director for a term of four years until the close of the ordinary General Meeting of 2030.
This resolution is approved as follows:
| For | 144 956 974 | 89.58% |
|---|---|---|
| Against | 16 859 969 | 10.42% |
| Abstention | 5 021 |
SPECIAL PART
9 Renewal of approval of a change of control provisions in the EMTN Program - art. 7:151 of the BCCA
Pursuant to article 7:151 of the BCCA, the General Meeting is solely competent to approve so-called ‘change of control’ clauses, i.e., provisions whereby third parties are granted rights having a substantial influence on the assets of the Company or causing a substantial debt or liability for the Company, if the exercise of such rights depends on the launch of a public takeover bid on the shares of the Company or a change of control thereof. These clauses are standard requests from our creditors and/or in the legal documentation of our financing arrangements.
UCB SA/NV has established a Euro Medium Term Note Program on 6 March 2013 for an amount of EUR 5 000 000 000, with last update of the Base Prospectus on 17 October 2023, as this program may be further amended, extended or updated from time to time (the “EMTN Program”). The terms of the EMTN Program provide for a change of control clause - condition 5 (e) (i) - under which, for any of the Notes issued under the EMTN Program where a change of control put is included in the relevant final terms, any and all of the holders of such notes can, in certain circumstances, require UCB SA/NV to redeem that Note, following a change of control at the level of UCB SA/NV, upon exercise of the change of control put, for a value equal to the put redemption amount increased with, if appropriate, interest accrued until the date of exercise of the change of control put (all as more particularly described in the Base Prospectus of the EMTN Program).
In accordance with article 7:151 of the BCCA, this clause must be approved by the General Meeting, and it is hereby proposed to renew this approval for any series of notes issued
under the EMTN Program including such clause to the extent the Program is renewed to allow for such issuance, from 30 April 2026 until 29 April 2027.
Pursuant to article 7:151 of the BCCA, the General Meeting renews its approval: (i) of condition 5 (e) (i) of the Terms and Conditions of the EMTN Program (Redemption at the Option of Noteholders – Upon a Change of Control (Change of Control Put)), in respect of any series of notes to which such condition is made applicable being issued under the Program, to the extent the Program is renewed to allow for such issuance, from 30 April 2026 until 29 April 2027, under which any and all of the holders of the relevant notes can, in certain circumstances when a Change of Control at the level of UCB SA/NV occurs, require UCB SA/NV to redeem that note on the Change of Control Put Date at the Put Redemption Amount together, if applicable, with interest accrued to such Change of Control Put Date, following a Change of Control of UCB SA/NV; and (ii) of any other provision of the EMTN Program or notes issued under the EMTN Program granting rights to third parties which could affect an obligation on UCB SA/NV where in each case the exercise of these rights is dependent on the occurrence of a Change of Control.
This resolution is approved as follows:
| For | 161 082 595 | 99.79% |
|---|---|---|
| Against | 333 799 | 0.21% |
| Abstention | 405 570 |
The agenda of the General Meeting having been entirely covered, the Chair thanked the meeting, and the Secretary was exempted by the Assembly from reading the minutes.
The minutes are drawn up in French and Dutch (with a free translation in English for information purposes only) and are signed by the Chairman, the Secretary, the Scrutineers, and the other members of the bureau, by Mr. Bart De Vrij, the proxyholder designated by the Board of Directors, and the shareholders or proxyholders who wish to do so. The minutes shall be made available online within 15 days from the General Meeting, in accordance with the law.
The Chair declares the Annual General Meeting closed.
The meeting is closed at 12:50.
Brussels, 30 April 2026.
[Signed]